Targeting long non-coding RNAs (lncRNAs) with oligonucleotides in cancer therapy

Mark R. Pickard¹, Gwyn T. Williams²

¹Chester Centre for Stress Research, Institute of Medicine, Bache Hall, University of Chester, Chester, UK; ²Apoptosis Research Group, School of Life Sciences, Huxley Building, Keele University, Keele, UK

Correspondence to: Mark R. Pickard. Institute of Medicine, Bache Hall, University of Chester, Chester CH2 1BR, UK. Email: m.pickard@chester.ac.uk; Gwyn T. Williams. Apoptosis Research Group, School of Life Sciences, Huxley Building, Keele University, Keele ST5 5BG, UK. Email: g.t.williams@keele.ac.uk.

Submitted Sep 20, 2016. Accepted for publication Sep 23, 2016.
doi: 10.21037/tcr.2016.10.63
View this article at: http://dx.doi.org/10.21037/tcr.2016.10.63

The Commentaries on our recent paper in Oncotarget (1), reporting the successful induction of apoptosis by a 23-base oligonucleotide mimicking a key section of lncRNA GAS5, have raised some important points and have further developed the broader application of lncRNA-targeting oligonucleotides in cancer therapy. This area is now attracting considerable attention, reflecting the rapidly growing awareness of the importance of lncRNAs in human cell biology and biomedicine—the numbers of citations of lncRNA papers are currently doubling every year (2), and this is recognised in all three Commentaries (3-5).

Fayda and Gezer (3) have emphasised the importance of such attempts to improve the therapy of breast cancer, in particular the therapy of triple-negative breast cancer, a particularly malignant and chemotherapy resistant form of the disease (6). They refer to one of the most important results of the original Oncotarget paper (1), i.e., that the 23-base oligonucleotide induced apoptosis in a triple-negative breast cancer line as well as in other breast-cancer lines. It is therefore particularly important to explore entirely novel opportunities, such as those presented by the emerging study of the lncRNAs, to produce and develop better treatments for clinically challenging cancers.

Both Fayda and Gezer (3) and Kino and Marr (4) rightly highlight the importance of future work on the lncRNA concerned, GAS5, to identify the steroid hormone receptor involved in the induction of apoptosis both by full-length GAS5 and by the 23-base oligonucleotide mimic. GAS5 does not interact with the oestrogen receptor (7), so its functional effects must be due to interaction with another, as yet unidentified, steroid hormone pathway.

Kino and Marr (4) provide further information on GAS5, i.e., that it is a host gene for small nucleolar RNAs (snoRNAs) (8,9), and go on to discuss in some detail a key remaining question—how to improve the properties of oligonucleotides, such as the GAS5 hormone response element mimic (1), for practical clinical application. One particularly encouraging factor is that the obstacles to successful clinical use for the GAS5 hormone response element mimic are broadly the same as those faced by other oligonucleotide therapies, and these are being addressed enthusiastically by many laboratories because of the immense potential of highly specific therapies targeting a range of RNAs. The three Commentaries recognise that the Oncotarget paper (1) helps to provide proof-of-principle for the use of oligonucleotides targeting lncRNAs, and so may be adapted for other lncRNA classes, such as those involved in the control of transcription (e.g., in epigenetic mechanisms), RNA processing and cell signaling pathways [reviewed by Morris and Mattick (10)]. Since most of the genome encodes lncRNAs (in contrast to the 2% or so that encodes protein-coding RNAs), we can deduce that the number of possible targets for improved cancer therapies is likely to be very large and the broad exploitation of this approach may prove very productive.

Acknowledgements

This work was supported by Breast Cancer Now, Prostate Cancer UK and Bloodwise.
Footnote

Provenance: This is a Guest Correspondence commissioned by Section Editor Long Chen (Department of PET-CT Center at the Yunnan Tumor Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China; Department of Biochemistry and Molecular Biology of Kunming Medical University, Kunming, China). Conflicts of Interest: The authors have no conflicts of interest to declare.


References

2. Web of Science. Available online: http://wok.mimas.ac.uk/

Cite this article as: Pickard MR, Williams GT. Targeting long non-coding RNAs (lncRNAs) with oligonucleotides in cancer therapy. Transl Cancer Res 2016;5(Suppl 4):S926-S927. doi: 10.21037/tcr.2016.10.63